A breakthrough in cancer treatment, a personalized mRNA vaccine has been developed to prevent osteosarcoma relapse, a rare and aggressive bone cancer, with promising immune responses observed in the first patient.
In a significant advancement in cancer treatment, a personalized mRNA cancer vaccine has been developed to prevent the recurrence of osteosarcoma, a rare and aggressive type of bone cancer. This innovative treatment was made possible through a compassionate use allowance from the US Food and Drug Administration and represents a major step forward in personalized medicine and cancer care. The vaccine is custom-built to target newly formed abnormal proteins unique to the patient's cancer, with the goal of preventing its recurrence.
Unlike conventional cancer treatments, this vaccine uses messenger RNA technology to instruct the patient's immune system to target tumor-specific proteins. This same technology, which has revolutionized COVID-19 vaccines, is now being applied to oncology in a way that could prevent cancer recurrence, a critical challenge for patients with aggressive forms of the disease. Osteosarcoma has a recurrence rate of up to 40%, and 5-year survival estimates are only 20-30% following relapse. The patient is tolerating the treatment very well, and promising immune responses have been observed in blood biomarkers even after the first dose.
The development of this vaccine is a testament to the institution's commitment to innovation and collaboration. From sequencing the patient's tumor to identifying neoantigens and manufacturing the vaccine, every step was completed within the institution's facilities, and in just four months' time. The treatment leveraged existing studies of similar methods that could eventually prevent the recurrence of triple-negative breast cancer. In time, the researchers hope the treatment will be scalable so that medical centers around the world can personalize vaccines to treat other tumor-based cancers.
The project was led by a multidisciplinary team, which included Dr. John Cooke, medical director for the institution's Center for RNA Therapeutics. "This approach could transform cancer care," said Dr. Cooke. "The ability to design a vaccine that trains the immune system to recognize and attack cancer cells unique to each patient opens the door to treating many other cancer types." The vaccine design was not a single best guess that was rushed forward, but rather multiple candidates were designed, synthesized, and tested in human cells before moving forward with RNA synthesis. As the researchers continue to develop and refine this treatment, they are hopeful that it will pave the way for a new era in personalized cancer care.
